New hope for kids with swallowing trouble: drug targets esophageal inflammation
NCT ID NCT04394351
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested dupilumab (Dupixent) in 102 children with active eosinophilic esophagitis, a condition where white blood cells build up in the esophagus, causing pain and swallowing problems. The drug aims to reduce inflammation and improve tissue health. Results will show if dupilumab is safe and effective compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (Dupixent)
What this could lead to
If successful, dupilumab could offer a new treatment option for children with eosinophilic esophagitis, reducing inflammation and easing symptoms.
What could go wrong
This is a Phase 3 trial, but results may not confirm long-term benefit or safety. Side effects like injection reactions or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS (EOE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Study Site
Phoenix, Arizona, 85016, United States
-
Regeneron Study Site
Little Rock, Arkansas, 72202, United States
-
Regeneron Study Site
Los Angeles, California, 90027, United States
-
Regeneron Study Site
San Francisco, California, 94143, United States
-
Regeneron Study Site
Aurora, Colorado, 80045, United States
-
Regeneron Study Site
St. Petersburg, Florida, 33701, United States
-
Regeneron Study Site
Atlanta, Georgia, 30322, United States
-
Regeneron Study Site
Atlanta, Georgia, 30342, United States
-
Regeneron Study Site
Chicago, Illinois, 60611, United States
-
Regeneron Study Site
Indianapolis, Indiana, 46202, United States
-
Regeneron Study Site
Iowa City, Iowa, 52242, United States
-
Regeneron Study Site
Boston, Massachusetts, 02111, United States
-
Regeneron Study Site
Boston, Massachusetts, 02114, United States
-
Regeneron Study Site
Boston, Massachusetts, 02115, United States
-
Regeneron Study Site
Lincoln, Nebraska, 68510, United States
-
Regeneron Study Site
New York, New York, 10029, United States
-
Regeneron Study Site
New York, New York, 10032, United States
-
Regeneron Study Site
New York, New York, 10065, United States
-
Regeneron Study Site
Chapel Hill, North Carolina, 27599, United States
-
Regeneron Study Site
Cincinnati, Ohio, 45229, United States
-
Regeneron Study Site
Cleveland, Ohio, 44106, United States
-
Regeneron Study Site
Philadelphia, Pennsylvania, 19104, United States
-
Regeneron Study Site
Dallas, Texas, 75207, United States
-
Regeneron Study Site
Fort Worth, Texas, 76104, United States
-
Regeneron Study Site
Houston, Texas, 77030, United States
-
Regeneron Study Site
Milwaukee, Wisconsin, 53226, United States
-
Regeneron Study Site
London, Ontario, N6A 5W9, Canada